selexipag
Ligand Summary
an oral prostacyclin receptor (IP receptor) agonist that is structurally distinct from prostacyclin, indicated for the treatment of pulmonary arterial hypertension, selexipag is hydrolyzed by carboxylesterase 1 to yield its active metabolite, which is approximately 37-fold as potent as selexipag, selexipag and the active metabolite are selective for the IP receptor versus other prostanoid receptors (EP1-4, DP, FP and TP)
UNII: 5EXC0E384L
PubChem: 9913767
Guide to Pharmacology: 7552
ChEMBL: CHEMBL238804
DrugCentral: 5077
LyCHI: UQXJU3FH7KDL
Target Activities
6 Activities
Items per page:
1 – 6 of 6
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
Ki | ||||||
Ki | ||||||
EC50 | ||||||
IC50 | ||||||
EC50 | ||||||
Ki | AGONIST | |||||